MA29353B1 - Traitement de la maladie de parkinson, de l'apnee obstructive du sommeil, de la demence a corps de lewy, de la demence vasculaire, avec des ligands du recepteur h3 de l'histamine non-imidazole-alkylamines - Google Patents

Traitement de la maladie de parkinson, de l'apnee obstructive du sommeil, de la demence a corps de lewy, de la demence vasculaire, avec des ligands du recepteur h3 de l'histamine non-imidazole-alkylamines

Info

Publication number
MA29353B1
MA29353B1 MA30254A MA30254A MA29353B1 MA 29353 B1 MA29353 B1 MA 29353B1 MA 30254 A MA30254 A MA 30254A MA 30254 A MA30254 A MA 30254A MA 29353 B1 MA29353 B1 MA 29353B1
Authority
MA
Morocco
Prior art keywords
dementia
parkinson
disease
treatment
sleep apnea
Prior art date
Application number
MA30254A
Other languages
English (en)
French (fr)
Inventor
Jean-Charles Schwartz
Jeanne-Marie Lecomte
Original Assignee
Bioprojet Soc Civ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35169680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29353(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioprojet Soc Civ filed Critical Bioprojet Soc Civ
Publication of MA29353B1 publication Critical patent/MA29353B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4453Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA30254A 2005-04-01 2007-09-27 Traitement de la maladie de parkinson, de l'apnee obstructive du sommeil, de la demence a corps de lewy, de la demence vasculaire, avec des ligands du recepteur h3 de l'histamine non-imidazole-alkylamines MA29353B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05290727A EP1707203A1 (en) 2005-04-01 2005-04-01 Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
US66861805P 2005-04-06 2005-04-06

Publications (1)

Publication Number Publication Date
MA29353B1 true MA29353B1 (fr) 2008-03-03

Family

ID=35169680

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30254A MA29353B1 (fr) 2005-04-01 2007-09-27 Traitement de la maladie de parkinson, de l'apnee obstructive du sommeil, de la demence a corps de lewy, de la demence vasculaire, avec des ligands du recepteur h3 de l'histamine non-imidazole-alkylamines

Country Status (27)

Country Link
US (1) US8486947B2 (OSRAM)
EP (2) EP1707203A1 (OSRAM)
JP (3) JP5546761B2 (OSRAM)
KR (1) KR101308527B1 (OSRAM)
CN (1) CN101171009B (OSRAM)
AU (1) AU2006228413C1 (OSRAM)
BR (1) BRPI0612216B1 (OSRAM)
CA (1) CA2603656C (OSRAM)
CY (1) CY1114636T1 (OSRAM)
DK (1) DK1863487T4 (OSRAM)
EA (1) EA016007B1 (OSRAM)
ES (1) ES2426008T5 (OSRAM)
HR (1) HRP20130748T4 (OSRAM)
MA (1) MA29353B1 (OSRAM)
ME (1) ME01713B (OSRAM)
MX (1) MX2007012162A (OSRAM)
NO (1) NO343603B1 (OSRAM)
NZ (1) NZ561940A (OSRAM)
PL (1) PL1863487T5 (OSRAM)
PT (1) PT1863487E (OSRAM)
RS (1) RS52911B2 (OSRAM)
SG (1) SG147415A1 (OSRAM)
SI (1) SI1863487T2 (OSRAM)
TN (1) TNSN07365A1 (OSRAM)
UA (1) UA94902C2 (OSRAM)
WO (1) WO2006103546A2 (OSRAM)
ZA (1) ZA200708086B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
JP5203360B2 (ja) 2006-06-23 2013-06-05 アボット・ラボラトリーズ ヒスタミンh3受容体調節剤としてのシクロプロピルアミン誘導体
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
WO2008013838A2 (en) 2006-07-25 2008-01-31 Cephalon, Inc. Pyridizinone derivatives
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
MX2010008375A (es) 2008-01-30 2011-03-04 Cephalon Inc Star Derivados de piperidina espirocíclicos substituidos como ligandos de receptores de histamina-3 (h3).
FR2932479A1 (fr) 2008-06-13 2009-12-18 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
US9181275B2 (en) 2011-08-11 2015-11-10 Abbvie Inc. Mercaptoamidine derivatives and methods of use
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
KR20150064743A (ko) * 2012-10-05 2015-06-11 트랜스테크 파르마 엘엘씨 경도 및 중등도 알츠하이머 병의 치료
EP3391886A1 (en) 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder
US11266837B2 (en) 2019-03-06 2022-03-08 Medtronic Xomed, Inc. Position sensitive lingual muscle simulation system for obstructive sleep apnea
EP4248969A1 (en) 2022-03-23 2023-09-27 Bioprojet Use of pitolisant for treating severe fatigue
KR20250165426A (ko) 2023-03-31 2025-11-25 바이오프로제 파르마 피톨리산트 염산염의 다형(多形) 형태
WO2025082972A1 (en) 2023-10-16 2025-04-24 Bioprojet Pharma Enteric coated pitolisant formulations and methods of use

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5815945A (ja) * 1981-07-21 1983-01-29 Teikoku Hormone Mfg Co Ltd 新規なフエノキシアルキルアミン誘導体
FR2579596B1 (fr) 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2671083B1 (fr) 1990-12-31 1994-12-23 Inst Nat Sante Rech Med Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques.
DK0573542T3 (da) 1991-02-27 1998-05-18 Seed Capital Investments Imidazolderivater med antagonistisk aktivitet over for histamin-H3-receptoren
EP0619818B1 (en) 1991-12-18 1996-07-10 Schering Corporation Imidazoylalkyl substituted with a six membered nitrogen containing heterocyclic ring
US5463074A (en) 1991-12-18 1995-10-31 Schering Corporation Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring
FR2686084B1 (fr) 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5380858A (en) 1992-04-01 1995-01-10 The University Of Toledo Process for the preparation of intermediates useful for the synthesis of histamine receptor antagonists
US5486526A (en) * 1992-04-01 1996-01-23 The University Of Toledo Histamine H3 -receptor antagonists and therapeutic uses thereof
US5639775A (en) 1992-04-01 1997-06-17 The University Of Toledo 4-[4'-piperodinyl or 3'-pirrolidinyl] substituted imidazoles as H3 -receptor antagonists and therapeutic uses thereof
WO1994017058A1 (fr) 1993-01-25 1994-08-04 The Green Cross Corporation Compose d'imidazole
JP3522790B2 (ja) 1993-06-08 2004-04-26 花王株式会社 H3−レセプター刺激薬
WO1995006037A1 (en) 1993-08-27 1995-03-02 Vrije Universiteit New imidazole derivatives having agonistic or antagonistic activity on the histamine h3 receptor
GB9319534D0 (en) * 1993-09-22 1993-11-10 Boots Co Plc Therapeutic agents
EP0729459B1 (en) 1993-11-15 2003-03-12 Schering Corporation Phenyl-alkyl imidazoles as h3-receptor antagonists
GB9411045D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Compounds and use
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
EP0841922B1 (en) 1995-05-30 2002-02-20 Gliatech, Inc. 1h-4(5)-substituted imidazole derivatives
US5652258A (en) 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives
JPH11507631A (ja) 1995-06-07 1999-07-06 グリアテツク・インコーポレイテツド 1h−4(5)−置換イミダゾール誘導体
RU2182904C2 (ru) 1996-02-09 2002-05-27 Джеймс Блэк Фаундейшн Лимитед Сульфонамиды и способы их получения
JP3925579B2 (ja) * 1998-02-03 2007-06-06 日本精工株式会社 潤滑剤供給体、並びに前記潤滑剤供給体を備える転がり軸受、リニアガイド装置及びボールねじ装置
EP0982300A3 (en) * 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
US6136559A (en) * 1998-10-07 2000-10-24 Ortho Pharmaceutical Corporation DNA encoding as human histamine receptor of the H3 subtype
PL196773B1 (pl) * 1999-06-11 2008-01-31 Toyama Chemical Co Ltd Pochodna N-alkiloksyalkilo-N,N-dialkiloaminy lub jej sole oraz środek zawierający ten związek stosowany do leczenia chorób neurodegeneratywnych
GB9924941D0 (en) * 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
US6620839B2 (en) * 2000-07-13 2003-09-16 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
DE60117814T2 (de) * 2000-08-08 2006-11-02 Ortho-Mcneil Pharmaceutical, Inc. Nicht-imidazol aryloxyalkylamine als h3 rezeptor liganden
US6794405B2 (en) * 2000-08-17 2004-09-21 Merck & Co., Inc. Alicyclic imidazoles as H3 agents
AU2001283573A1 (en) * 2000-08-21 2002-03-04 Gliatech, Inc. The use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity
ES2299596T3 (es) * 2001-03-29 2008-06-01 Ortho Mcneil Pharmaceutical, Inc. Derivados de imidazol utiles como ligandos del receptor h3 de la histamina.
EP1451225A1 (en) * 2001-11-15 2004-09-01 Ortho-McNeil Pharmaceutical, Inc. Agonists of recombinant human histamine h3 receptor
CA2469893A1 (en) * 2001-12-10 2003-06-19 Ortho-Mcneil Pharmaceutical, Inc. Phenylalkynes
AU2003287206A1 (en) * 2002-10-23 2004-05-13 Janssen Pharmaceutica, N.V. Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators
FR2856596B1 (fr) * 2003-06-27 2007-04-27 Bioprojet Soc Civ Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes.
US7595316B2 (en) * 2003-06-27 2009-09-29 Banyu Pharmaceutical Co., Ltd. Heteroaryloxy nitrogenous saturated heterocyclic derivative
SE0302116D0 (sv) * 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
WO2005028438A1 (ja) * 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体

Also Published As

Publication number Publication date
SI1863487T1 (sl) 2013-09-30
AU2006228413B2 (en) 2011-09-15
DK1863487T3 (da) 2013-08-12
CN101171009B (zh) 2012-11-07
EP1863487B2 (en) 2019-07-17
CY1114636T1 (el) 2016-10-05
EP1707203A1 (en) 2006-10-04
BRPI0612216A2 (pt) 2010-10-26
EP1863487B1 (en) 2013-05-29
SG147415A1 (en) 2008-11-28
JP2014062126A (ja) 2014-04-10
PL1863487T5 (pl) 2021-08-09
CN101171009A (zh) 2008-04-30
US20090318433A1 (en) 2009-12-24
PT1863487E (pt) 2013-08-29
HRP20130748T1 (en) 2013-10-11
ES2426008T3 (es) 2013-10-18
EP1863487A2 (en) 2007-12-12
JP2008534572A (ja) 2008-08-28
ZA200708086B (en) 2008-10-29
ME01713B (me) 2014-09-20
KR20080002904A (ko) 2008-01-04
WO2006103546A3 (en) 2007-03-01
KR101308527B1 (ko) 2013-09-17
EA016007B1 (ru) 2012-01-30
NO343603B1 (no) 2019-04-08
JP5955872B2 (ja) 2016-07-20
HRP20130748T4 (hr) 2019-11-15
MX2007012162A (es) 2007-11-22
EA200702135A1 (ru) 2008-04-28
TNSN07365A1 (fr) 2008-12-31
ES2426008T5 (es) 2020-03-20
WO2006103546A2 (en) 2006-10-05
NO20075086L (no) 2007-12-27
CA2603656C (en) 2015-06-16
JP2016106142A (ja) 2016-06-16
AU2006228413A1 (en) 2006-10-05
UA94902C2 (ru) 2011-06-25
CA2603656A1 (en) 2006-10-05
RS52911B2 (sr) 2019-11-29
US8486947B2 (en) 2013-07-16
DK1863487T4 (da) 2019-10-14
NZ561940A (en) 2010-06-25
RS52911B (sr) 2014-02-28
BRPI0612216B1 (pt) 2022-04-19
JP5546761B2 (ja) 2014-07-09
AU2006228413C1 (en) 2012-02-02
SI1863487T2 (sl) 2019-11-29
PL1863487T3 (pl) 2014-10-31

Similar Documents

Publication Publication Date Title
MA29353B1 (fr) Traitement de la maladie de parkinson, de l'apnee obstructive du sommeil, de la demence a corps de lewy, de la demence vasculaire, avec des ligands du recepteur h3 de l'histamine non-imidazole-alkylamines
CY1122724T1 (el) Ρυθμιση της δραστικοτητας των προνευροτροφινων
EP1717235A3 (en) Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
ATE435862T1 (de) Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
EP1868528A4 (en) METHOD FOR FORMING AN IMPROVED STENT FROM A METAL ALLOY
EP2119443A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF DISEASES RELATED TO A THROMBUS OR EMBOLUS
CY2015025I2 (el) Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
DE602007001893D1 (en) Aryl-4-ethinylisoxazolderivate
WO2004074246A3 (en) Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
MX2009000385A (es) Acil-anilidas sustituidas y metodos de uso de las mismas.
MX2009004900A (es) Arilamidas sustituidas por tiazol u oxazol.
SI1729753T1 (sl) Uporaba antagonistov NMDA receptorjev za zdravljenje tinitusa povzročenega s kohlearno eksitotoksičnostjo
EP2416795A4 (en) COGNITIVE DECLINE INHIBITORS
GB2462235A (en) NMDA and MC receptor antagonists exhibiting neuroprotective and memory enhancing activities
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
EP1807396A4 (en) 2-AMINOPYRIDINE COMPOSITIONS AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF MORBUS ALZHEIMER
EP2140882A4 (en) MEDICINE FOR THE TREATMENT OF LUNG DISEASES
EP3730144A4 (en) AGENTS FOR TREATMENT OF DISEASES OF THE NERVOUS SYSTEM
TW200509920A (en) Imidazole derivatives
EP1817311A4 (en) 2,3,4,6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS AS BETA SEKTRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
EP1814537A4 (en) MACROCYCLIC TERTIARY AMIN BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
PL4284387T3 (pl) Terapia podnosząca poziom NAD w chorobie Parkinsona
EA200701984A1 (ru) Конденсированные тиазольные производные, обладающие сродством к гистаминовому h3 рецептору
EP1813596A4 (en) PROCESS FOR PREPARING ALPHA, ALPHA-DIFLUORAMINE
FR2905290B1 (fr) Dispositif de traitement pour le grenaillage de la surface interieure d'une piece tubulaire